印度非专利药品制造商推出50+西磁石化药物专利到期后药品,降低价格,增加获得糖尿病和减重治疗的机会。 Indian generic makers launch 50+ semaglutide drugs post-patent expiry, slashing prices and boosting access to diabetes and weight-loss treatments.

印度非专利药商,包括Ajanta Pharma、Reddy博士、Lupin、Mankind Pharma和Sun Pharma等印度非专利药商,将在Novo Nordisk的Ozempic和Wegovy3月20日专利到期后发射50多种基于Semaglutide的非专利药。 Indian generic drugmakers, including Ajanta Pharma, Dr. Reddy’s, Lupin, Mankind Pharma, and Sun Pharma, are set to launch over 50 semaglutide-based generics following the March 20 patent expiry of Novo Nordisk’s Ozempic and Wegovy. 这标志着印度是继加拿大之后失去专利保护的第二个国家,有可能将价格降低高达50%,达到每周5 000美元左右(54美元)。 This marks India as the second country after Canada to lose patent protection, potentially cutting prices by up to 50% to around ₹5,000 ($54) per week. 随着医院扩大肥胖症护理服务,并与制药公司和远程保健平台合作,供应量的激增有望增加获得糖尿病和体重管理GLP-1类药物的机会。 The surge in availability is expected to boost access to GLP-1 drugs for diabetes and weight management, with hospitals expanding obesity care services and partnering with pharma firms and telehealth platforms. 销售量正在迅速增长,这一类别逐年增长177%,尽管专家告诫不要在没有适当监测的情况下广泛开处方,以避免高辍学率。 Sales volumes are rising rapidly, with the category growing 177% year-on-year, though experts caution against broad prescribing without proper monitoring to avoid high dropout rates. 由印度庞大超重人口及不断扩大的医疗保健基础设施所驱动, 到2030年, 市场可能会从1 000 克郎增长至5 000 克郎。 The market could grow from ₹1,000 crore to ₹5,000 crore by 2030, driven by India’s large overweight population and expanding healthcare infrastructure.